Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Restructuring Costs (2024 - 2025)

Editas Medicine (EDIT) has disclosed Restructuring Costs for 2 consecutive years, with $26.1 million as the latest value for Q2 2025.

  • On a quarterly basis, Restructuring Costs changed N/A to $26.1 million in Q2 2025 year-over-year; TTM through Sep 2025 was $79.2 million, a N/A change, with the full-year FY2024 number at $12.2 million, changed N/A from a year prior.
  • Restructuring Costs was $26.1 million for Q2 2025 at Editas Medicine, down from $40.9 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $40.9 million in Q1 2025 to a low of $12.2 million in Q4 2024.